Global siRNA Therapeutics Market By Delivery Technology, Route, Indication, Distribution Channel, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035

The siRNA therapeutics market is experiencing significant expansion, driven by rapid advancements in RNA interference technology, increasing adoption of precision medicine approaches, and growing investment in innovative drug development platforms. The market was estimated to be valued at approximately USD 2.1 billion in 2025 and is projected to reach around USD 9.0 billion by 2035, expanding at a compound annual growth rate (CAGR) of 15.7% during the forecast period from 2026 to 2035.

A major factor contributing to market expansion is the rising demand for precision medicine solutions that address the underlying genetic mechanisms of disease rather than only managing symptoms. siRNA therapeutics offer the ability to selectively inhibit the expression of disease-associated genes, creating opportunities for treating a wide range of conditions, including rare genetic disorders, metabolic diseases, cardiovascular conditions, and other chronic illnesses.

Noteworthy Market Developments

The siRNA therapeutics market is characterized by the presence of several highly innovative biotechnology and pharmaceutical companies that have established strong competitive positions through proprietary delivery technologies, expanding clinical pipelines, and successful commercialization strategies. Among the leading players, Alnylam Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, Novo Nordisk, and Silence Therapeutics have emerged as the top companies shaping the evolution of RNA interference-based medicines.

Alnylam Pharmaceuticals is widely recognized as the pioneer and leading company in the siRNA therapeutics market, with a strong foundation built on decades of research and innovation in RNA interference technology. Novartis has secured a prominent position in the siRNA therapeutics market through its commercialization of Leqvio (inclisiran), an innovative siRNA therapy designed for the management of cardiovascular disease by reducing low-density lipoprotein cholesterol (LDL-C) levels.

Arrowhead Pharmaceuticals has emerged as a highly competitive player through its proprietary TRiM(TM) (Targeted RNAi Molecule) platform, which is designed to enhance the delivery and effectiveness of RNA interference therapies. Novo Nordisk has significantly strengthened its position in the siRNA therapeutics sector through the acquisition of Dicerna Pharmaceuticals, a move that expanded its capabilities in RNA interference research and therapeutic development.

Silence Therapeutics represents another important innovator in the siRNA therapeutics space, supported by its proprietary mRNAi GOLD(TM) platform, which focuses on developing highly targeted RNA interference medicines. The company's platform is designed to optimize siRNA molecule design and delivery, enabling the development of therapies with improved specificity and therapeutic potential.

Core Growth Driver

Accelerated regulatory support and increased funding availability have become major factors driving the growth of the siRNA therapeutics market. As RNA interference technologies continue to demonstrate strong potential in addressing rare genetic disorders, metabolic diseases, and other conditions with significant unmet medical needs, regulatory agencies and funding organizations have placed greater emphasis on supporting the development of innovative RNA-based medicines. Favorable regulatory initiatives, financial incentives, and streamlined approval mechanisms are helping pharmaceutical and biotechnology companies advance siRNA candidates more efficiently from discovery stages to commercial availability.

Emerging Opportunity Trends

AI-driven target discovery and sequence design represent an emerging opportunity trend that is expected to significantly influence the future growth trajectory of the siRNA therapeutics market. The integration of artificial intelligence (AI), machine learning, and advanced computational biology into RNA interference research is transforming the way researchers identify therapeutic targets, design siRNA molecules, and optimize drug candidates. By improving the speed, accuracy, and efficiency of early-stage discovery processes, AI-enabled platforms are helping overcome several traditional challenges associated with the development of siRNA-based medicines.

Barriers to Optimization

The high cost of treatment and increasing payer pressure represent significant challenges that may restrain the growth of the siRNA therapeutics market. Although siRNA-based medicines offer innovative and highly targeted approaches for treating complex genetic and metabolic disorders, their advanced development processes, specialized manufacturing requirements, and sophisticated delivery technologies contribute to substantially higher treatment costs compared with conventional therapies. siRNA therapies often command annual treatment costs ranging from approximately $300,000 to $450,000 or more per patient, depending on the specific therapy, indication, dosing frequency, and healthcare market. The premium pricing associated with these next-generation medicines creates affordability concerns for patients, healthcare providers, insurers, and government healthcare systems, particularly as adoption expands into broader patient populations.

Detailed Market Segmentation

By delivery technology, GalNAc conjugates established a dominant position in the siRNA therapeutics market in 2025, representing a major breakthrough in overcoming one of the most significant challenges in RNA interference-based medicine: efficient and targeted delivery of siRNA molecules to the desired cells. The success of GalNAc conjugation technology has transformed the development and commercialization potential of siRNA therapies by providing a highly effective mechanism for directing therapeutic payloads to liver cells. This advancement has enabled pharmaceutical developers to improve treatment precision, enhance therapeutic performance, and reduce many of the limitations historically associated with RNA-based drug delivery.

By route of administration, the subcutaneous delivery route accounted for the largest revenue share in the siRNA therapeutics market in 2025, representing a significant shift in how RNA interference-based treatments are administered and managed in clinical practice. The growing preference for subcutaneous administration is closely linked to the need for more convenient, patient-friendly, and sustainable delivery approaches for advanced genetic medicines. As siRNA therapies continue to move from specialized clinical settings toward broader real-world use, the ability to provide effective treatment through simpler administration methods has become a key factor influencing market adoption.

By indication, rare and metabolic disease applications accounted for the dominant share of the siRNA therapeutics market in 2025, reflecting the strong commercial potential of RNA interference-based treatments in addressing conditions with significant unmet medical needs. The leadership of this segment is supported by the increasing development and approval of targeted siRNA therapies designed to regulate disease-causing genes associated with inherited disorders, metabolic abnormalities, and other complex conditions.

By Distribution Channel, as of 2026, specialty pharmacies have emerged as the leading segment in the small interfering RNA (siRNA) therapeutics market, accounting for more than 62% of global distribution sales. This significant market dominance reflects the specialized nature of siRNA-based treatments. This often requires advanced handling, dedicated patient support services, and coordinated delivery systems that are beyond the capabilities of conventional pharmacy networks. The growing adoption of RNA interference (RNAi) therapies for complex and rare diseases has further strengthened the role of specialty pharmacies as the preferred channel for ensuring effective access, administration, and long-term treatment management.

Segment Breakdown

By Delivery Technology

• GalNAc Conjugate
• Lipid Nanoparticle
• Polymer/Other

By Route

• Subcutaneous
• Intravenous
• Intrathecal/CNS

By Indication

• Rare/Metabolic
• hATTR Amyloidosis
• Hyperoxaluria
• Porphyria
• Cardiovascular/Dyslipidemia
• Oncology
• Others

By Distribution Channel

• Hospital Pharmacy
• Specialty Pharmacy

By End User

• Hospitals
• Specialty Clinics
• Homecare

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America

Geography Breakdown

• In 2026, North America firmly established itself as the leading regional market, accounting for the largest share of global revenue and maintaining a dominant position within the industry. This leadership is primarily driven by the United States, which contributes more than 85% of the region's overall commercial activity. The country's well-developed healthcare ecosystem, advanced pharmaceutical infrastructure, and strong commercialization capabilities have created an ideal environment for the widespread adoption of innovative therapeutic technologies.
• A major factor supporting the United States' market leadership is its favorable buy-and-bill reimbursement model, which enables healthcare providers to purchase high-cost injectable therapies and subsequently receive reimbursement from insurers after administration. This reimbursement framework significantly reduces financial barriers for hospitals and specialty clinics, encouraging the adoption of premium therapeutics while facilitating smoother clinical integration.
• The United States also benefits from the strong presence of globally recognized pharmaceutical and biotechnology companies that continue to invest heavily in research, development, and commercialization. These industry leaders maintain extensive research facilities, manufacturing capabilities, and strategic partnerships with academic institutions and healthcare organizations, enabling the rapid progression of clinical pipelines.

Leading Market Participants

• Alnylam Pharmaceuticals
• Novartis
• Novo Nordisk (Dicerna)
• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals
• Silence Therapeutics
• Regeneron
• Sanofi
• Moderna
• Roche
• Amgen
• Eli Lilly
• Comanche Biopharma
• Quark Pharmaceuticals
• Astellas
• Other Prominent Players